Results 71 to 80 of about 381,135 (230)

Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey

Bleeding, Thrombosis and Vascular Biology
Background: a survey was launched to assess the challenges that Italian patients and physicians face with home prophylaxis using low-molecular-weight heparin (LMWH), promoted by the "Arianna Anticoagulazione" Foundation, Bologna, Italy.
Stefania Cavazza, Gualtiero Palareti
doaj   +1 more source

Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism

Thrombosis Journal, 2011
Background The prevention of venous thromboembolism has been identified as a leading priority in hospital safety. Recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include ...
Adiguzel Cafer, Fareed Jawed, Thethi Indermohan   +2 more
doaj   +1 more source

Rational Design of Anticoagulant Drugs Using Oligosaccharide Chemistry

CHIMIA, 2011
For a long time, heparin and low molecular weight heparins have been the drugs of choice for the management of thrombosis. Discovery of the antithrombin binding domain in heparin, a critical element in the anticoagulant activity of this ...
Ahmed El Hadri, Maurice Petitou
doaj   +1 more source

Postoperative care in finger replantation. Our case-load and review of the literature [PDF]

, 2015
OBJECTIVE: Technical success of a finger replantation depends on several factors such as surgical procedure, type of injury, number of segments amputated, amputation level and individual patient factors.
Chen, Hc, Cigna, Emanuele, LO TORTO, Federico, Maruccia, Michele, Ribuffo, Diego, Ruggieri, M, Zaccheddu, F   +6 more
core  

Risk Factors of Bleeding after Subcutaneous Injection of Low-molecular-weightHeparin in Elderly Patients with Unstable Angina Pectoris and Asthenia

Guoji laonian yixue zazhi
Objective To analyze the risk factors of bleeding after subcutaneous injection of low-molecular-weight heparin in elderly patients with unstable angina pectoris and weakness.
Qi Wu, Meili Ji, Rong Zhang, Danlei Wang, Peipei Xia   +4 more
doaj   +1 more source

Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells

Brazilian Journal of Medical and Biological Research, 2001
The anticlotting and antithrombotic activities of heparin, heparan sulfate, low molecular weight heparins, heparin and heparin-like compounds from various sources used in clinical practice or under development are briefly reviewed.
H.B. Nader, M.A.S. Pinhal, E.C. Baú, R.A.B. Castro, G.F. Medeiros, S.F. Chavante, E.L. Leite, E.S. Trindade, S.K. Shinjo, H.A.O. Rocha, I.L.S. Tersariol, A. Mendes, C.P. Dietrich   +12 more
doaj   +1 more source

Sulfonated copolymers as heparin-mimicking stabilizer of fibroblast growth factor : size, architecture, and monomer distribution effects [PDF]

, 2018
Fibroblast growth factors (FGF) are involved in a wide range of biological processes such as cell proliferation and differentiation. In living organisms, the binding of FGF to its receptors are mediated through electrostatic interactions between FGF and ...
Bray, Caroline, Gurnani, Pratik, Mansfield, Edward D. H., Peltier, Raoul, Perrier, Sébastien   +4 more
core   +2 more sources

Low molecular weight heparin-induced thrombocytopenia management during hemodialysis and cardiac surgery: a case report and literature review

JA Clinical Reports
Background Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy, including low molecular weight heparins (LMWHs) like dalteparin.
Shuto Takada, Shogo Suzuki, Takahiro Tamura   +2 more
doaj   +1 more source

Best Practice for Administering Low Molecular Weight Heparin (LMWH) Injection: An Evidence-Based Practice Project

Evidence-Based Nursing Research
Context: Anticoagulation with subcutaneous heparin is the most common treatment for thromboembolic illnesses. LMWH is currently the most popular parenteral anticoagulant drug. Low molecular weight heparins are given by subcutaneous injection.
Faisal A. Alasmari, Mohammad A. Hazazi, Ebtisam A. Ebrahim, Mirshad T. Thazha, Daoud A. Alkouz, Hadeel Y. ALhawsawi, Rudayna H. Al Romaili, Thaer W. Almalad   +7 more
doaj   +1 more source

Low Molecular Weight Heparin Overdose: A 10 Year Case Series [PDF]

Asia Pacific Journal of Medical Toxicology, 2013
Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage.
Adeline Ngo, Daryl Tan, Kent Olson
doaj